Loading
Adding three years of hormone therapy to radiotherapy for locally advanced prostate cancer improved five-year survival from 62 to 79 percent, establishing long-term androgen deprivation with radiotherapy as the standard for high-risk disease.
Phase 3 trial of 415 men with locally advanced (T3 to T4 or high-grade T1 to T2) prostate cancer randomised to external beam radiotherapy alone or with goserelin started at the beginning of radiotherapy and continued for three years.
Five-year overall survival was 79 versus 62 percent and disease-free survival 85 versus 48 percent; ten-year follow-up confirmed a persistent survival benefit (58.1 versus 39.8 percent).
Long-term androgen deprivation (18 to 36 months) with radiotherapy remains the backbone for high-risk localised prostate cancer, to which abiraterone is now added for the highest-risk men.
Shares Localised prostate cancer, high and very high risk, New England Journal of Medicine.
Shares Localised prostate cancer, high and very high risk, New England Journal of Medicine.
Shares Localised prostate cancer, high and very high risk, New England Journal of Medicine.
Shares Localised prostate cancer, high and very high risk, New England Journal of Medicine.